Molecular mechanism of chemical-induced toxicity in fetal livers
Molecular mechanism of chemical-induced toxicity in fetal livers
批准号:
17390034
负责人:
YAMAZAKI Hiroshi
金额:
$10.07万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2005
资助国家:
日本
项目状态:
已结题
起止时间:
2005 至 2007
中文摘要
我们发现了人肝微粒体药物代谢的一些新结果。1)伏立康唑((2R, 3S)-2-(2,4 -二氟苯i)-3-(5-氟-4-嘧啶i)-1-(1h - 1,2,4 -三唑-1-基)-2-丁醇)是一种新型的口服和静脉制剂。人体体内研究表明,伏立康唑被广泛代谢,只有不到2%的剂量被排出。细胞色素CYP2C19、CYP2C9和CYP3A4参与伏立康唑n -氧化的研究已在人肝微粒体中得到证实。为了确认P450亚型在个体伏立康唑清除中的确切作用,我们研究了重组P450亚型催化的伏立康唑氧化代谢以及CYP2C19基因分型的人肝微粒体。在大肠杆菌表达系统的重组P450亚型中,CYP2C19和CYP3A4具有伏立康唑n氧化活性,而CYP2C92不具有。异丙酚(2,6 -二异丙酚)用于诱导麻醉和维持麻醉或镇静。即使在相对较长时间静脉输注异丙酚后,其快速和完全恢复的优点可归因于母体化合物的广泛生物转化,主要是在肝脏中。然而,长期和大剂量异丙酚输注与进展性心肌衰竭的发展有显著关联。虽然有一些关于异丙酚在人体内的药代动力学和药物相互作用的报道,但个体P450酶在异丙酚处置中的作用仍然未知。本研究利用重组人P450酶和肝微粒体研究了人P450酶参与异丙酚4-和ω-羟基化的作用。在重组人P450酶体系中,CYP2B6、CYP1A2和CYP3A4表现出较高的异丙酚4-羟基化活性。相反,异丙酚的ω-羟基化反应主要由CYP2B6.3催化。沙利度胺在治疗多种癌症和炎症性疾病方面是一种很有前景的药物。另一方面,关于对代谢酶的影响的报道很少。我们研究了沙利度胺对人肝微粒体细胞色素P450的影响。目前的结果表明咪达唑仑的总清除率将以剂量依赖的方式增加。沙利度胺可能引起的药物相互作用较少
英文摘要
We found several new results of drug metabolism in human liver microsomes. 1) Voriconazole ((2R, 3S)-2-(2, 4-difluorophenyI)-3-(5-fluoro-4-pyrimidiny1)-1-(1H-1, 2, 4-triazol-1-yl)-2-butanol) is a new antifungal agent developed as oral and intravenous formulations. In vivo studies in humans have indicated that voriconazole is extensively metabolized with less than 2% of the dose excreted unchanged. Involvement of cytochrome CYP2C19, CYP2C9, and CYP3A4 in N-oxidation of voriconazole has been demonstrated using human liver microsomes. To confirm the precise roles of P450 isoforms in voriconazole clearance in individuals, we investigated the oxidative metabolism of voriconazole catalyzed by recombinant P450s as well as human liver microsomes genotyped for the CYP2C19 gene. Among recombinant P450 isoforms using Escherichia coli expression systems, CYP2C19 and CYP3A4 had voriconazole N-oxidation activities, but not CYP2C92) Propofol (2, 6-diisopropylphenol) is administered for the induction … More of anesthesia and maintenance of anesthesia or for sedation. The merit of rapid and complete recovery that occurs even after relatively prolonged intravenous infusions of propofol is attributable to the extensive biotransformation of the parent compound, primarily in the liver. However, a significant association with the development of progressive myocardial failure has been reported for long-term and high-dose propofol infusion. Although there are several reports on the propofol pharmacokinetics and drug interactions in humans, the roles of individual P450 enzymes in the propofol disposition are still unknown. In the present study, the roles of human P450 enzymes involved in propofol 4- and ω-hydroxylation were investigated with recombinant human P450s and liver microsomes. CYP2B6 and CYP1A2, followed CYP3A4, showed high activities of propofol 4-hydroxylation in recombinant human P450 enzyme systems. In the contrast, ω-hydroxylation of propofol was mainly catalyzed by CYP2B6.3) Thalidomide is a promising drug in the treatment of a number of cancers and inflammatory diseases. On the other hand, a little information was reported regarding effects on metabolizing enzymes. We investigated the effects of thalidomide on cytochrome P450 in human liver microsomes. The present results suggest that total midazolam clearance would be increased in a dose dependent manner. Thalidomide may cause drug interactions of co-administered medicines Less
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.2174/187231207779814355
发表时间:
2007-01-01
期刊:
Drug metabolism letters
影响因子:
--
作者:
[Shimizu, Makiko, Matsumoto, Yoshiaki, Yamazaki, Hiroshi]
通讯作者:
Yamazaki, Hiroshi
Genetic polymorphism of bile acid CoA:amino acid N-acyitransferase in Japanese in dividuals
日本人胆汁酸CoA:氨基酸N-酰基转移酶基因多态性
DOI:
--
发表时间:
2007
期刊:
Drug Metab Pharmacokinet. 22
影响因子:
--
作者:
[Tougou, K., Fukuda, T., Ito, T., Yamazaki, H., and Azuma, J.]
通讯作者:
J.
ヒト肝チトクロームP450触媒活性に及ぼすサリドマイドの影響
沙利度胺对人肝细胞色素P450催化活性的影响
DOI:
--
发表时间:
2008
期刊:
影响因子:
--
作者:
[村山 典恵, 柳田 千裕, 清水 万紀子, 山崎 浩史]
通讯作者:
山崎 浩史
Voriconazole methyl hydroxylation and N-oxidation catalyzed by CYP3A4 and CYP2C19 in human liver microsomes
CYP3A4和CYP2C19在人肝微粒体中催化伏立康唑甲基羟基化和N-氧化
DOI:
--
发表时间:
2008
期刊:
影响因子:
--
作者:
[Hiroshi, Yamazaki, Node, Murayama, Naoko, Imai, Takahisa, Nakane, Makiko, Shimizu]
通讯作者:
Shimizu
臨床薬理研究進行財団
临床药理学研究进展基金会
DOI:
--
发表时间:
2007
期刊:
影响因子:
--
作者:
[山崎 浩史, 清水 万紀子, 永島 里美, 村山 典恵]
通讯作者:
村山 典恵
共 58 条
Relevance to bioactivation and toxicity of thalidomide, pomalidomide, and lenalidomide by human cytochrome P450 3A enzymes in cultured placental cells and humanized-liver mice
-
批准号:17K08425
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.0万
-
财政年份:2017
-
负责人:YAMAZAKI Hiroshi
-
依托单位:
Mechanisms of resistance to molecularly targeted drugs for oral squamous cell carcinoma and investigation of countermeasures
-
批准号:16K11732
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.08万
-
财政年份:2016
-
负责人:YAMAZAKI Hiroshi
-
依托单位:
Development of Effective Markers for Resistance of Oral Squamous Cell Carcinoma to Molecular-targeting Drugs
-
批准号:25463120
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.16万
-
财政年份:2013
-
负责人:YAMAZAKI Hiroshi
-
依托单位:
Thalidomide increases cytochrome P450 activity and drug metabolism in liver through direct activation of nuclear receptor CAR and PXR
-
批准号:23590200
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.49万
-
财政年份:2011
-
负责人:YAMAZAKI Hiroshi
-
依托单位:
evaluationofeffectivenessoftheobjectiveexaminationforautism indeafchildren
-
批准号:22791642
-
项目类别:Grant-in-Aid for Young Scientists (B)
-
资助金额:$2.5万
-
财政年份:2010
-
负责人:YAMAZAKI Hiroshi
-
依托单位:
Role of cancer stem cells related molecules in oral squamous cell carcinoma
-
批准号:22592246
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.91万
-
财政年份:2010
-
负责人:YAMAZAKI Hiroshi
-
依托单位:
Molecular Mechanisms of Toxic Expression Induced by Endocrine Disruptors via AHR
-
批准号:15390040
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$8.64万
-
财政年份:2003
-
负责人:YAMAZAKI Hiroshi
-
依托单位:
Study on the separation of rac and meso isomers and the reactivity of group 4 bridged metallocene complexes
-
批准号:11640544
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$0.38万
-
财政年份:1999
-
负责人:YAMAZAKI Hiroshi
-
依托单位:
PREDICTION OF DRUG DISPOSITION BY HUMAN DRUG METABOLIZING ENZYMES
-
批准号:11557191
-
项目类别:Grant-in-Aid for Scientific Research (B).
-
资助金额:$3.01万
-
财政年份:1999
-
负责人:YAMAZAKI Hiroshi
-
依托单位:
Creation of Substitution Labile Pyrazolylborate Metal Complexes
-
批准号:09640675
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$0.96万
-
财政年份:1997
-
负责人:YAMAZAKI Hiroshi
-
依托单位:
国内基金
海外基金
登录
查看更多内容
水稻P450基因CYPa介导的除草剂代谢抗性机制研究及理性设计
-
批准号:32572441
-
项目类别:面上项目
-
资助金额:50.00万元
-
批准年份:2025
-
负责人:李娟
-
依托单位:
底物杂泛性的P450氧化酶的理性改造及其在倍半萜C-H键活化中的应用
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:饶历
-
依托单位:
细菌特殊萜合成酶及P450酶的挖掘与功能研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
丹参酮生物合成途径关键细胞色素P450酶的功能鉴定与利用研究
-
批准号:32570429
-
项目类别:面上项目
-
资助金额:50.00万元
-
批准年份:2025
-
负责人:王志标
-
依托单位:
P450酶催化区域发散性碳氢键羟基化反应多样性合成轴手性联烯醇化合物
-
批准号:22561054
-
项目类别:地区科学基金项目
-
资助金额:32.00万元
-
批准年份:2025
-
负责人:周晓建
-
依托单位:
P450催化氧杂环丁烷形成酶学机制研究
-
批准号:32571470
-
项目类别:面上项目
-
资助金额:50.00万元
-
批准年份:2025
-
负责人:杨成帅
-
依托单位:
白腐真菌Pleurotus ostreatus细胞色素P450酶在药物活性化合物降解中的作用与机制研究
-
批准号:2025JJ50102
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:卓睿
-
依托单位:
蛋白辅因子调控紫杉醇合成限速P450酶T5αOH催化特异性的机制研究
-
批准号:32571467
-
项目类别:面上项目
-
资助金额:50.00万元
-
批准年份:2025
-
负责人:程健
-
依托单位:
新型夹竹桃天蛾质型多角体病毒通过宿主P450基因CYP6B6调控病毒复制的分子机制研究
-
批准号:32560678
-
项目类别:地区科学基金项目
-
资助金额:32.00万元
-
批准年份:2025
-
负责人:况文东
-
依托单位:
面向手性含氮化合物合成的新型P450不对称碳氮成键酶的分子设计及催化机制研究
-
批准号:32571652
-
项目类别:面上项目
-
资助金额:50.00万元
-
批准年份:2025
-
负责人:陈杰
-
依托单位: